What changed in v.1:This is the first version of the living research paper, assembled fresh from three initial findings. The paper anchors on the FTC July 2024 interim staff report's indication that PBM rebate agreements are conditioned on excluding lower-cost generics, then maps the PCMA membership and litigation record as a structural context for understanding how the same vertically integrated entities fund the trade group litigating against disclosure requirements. The 'What the record does not show' section is deliberately expansive at v.1, flagging six documented gaps — including unquantified advocacy funding flows, unreleased 6(b) contractual language, and absent state AG findings — that represent the investigation's next-priority targets.
The FTC Interim PBM Report (July 2024) and the Public Record on Rebate Retention, Formulary Design, and Advocacy Coordination
The FTC's July 2024 interim staff report on prescription drug middlemen indicates that pharmacy benefit managers — including Express Scripts — negotiate drug rebates that are "expressly conditioned on limiting access to potentially lower-cost generic and biosimilar competitors," a practice the report notes occurs without "transparency or accountability to the public" 1. The three largest PBMs — CVS Caremark, OptumRx, and Express Scripts (Cigna/Evernorth) — are simultaneously listed as core funding members of their principal trade group, PCMA, which public records show has served as the central litigant in major federal challenges to state PBM oversight laws 2.
Formulary Design and Rebate Conditionality: What the FTC Record Indicates
The FTC interim report's most concrete finding, per the public record, is that PBM–manufacturer agreements appear structured to exclude lower-cost drugs from formularies in exchange for higher rebates on brand-name products.
The FTC July 2024 interim staff report — produced under Section 6(b) special orders issued to major PBMs including Express Scripts and its rebate aggregator Zinc Health Services — indicates that PBMs and brand manufacturers enter agreements to exclude lower-cost competitor drugs from formularies in exchange for increased rebates 1. The report's language, as reflected in the public record, is that these arrangements operate without meaningful transparency to the public or accountability mechanisms. The record does not, at this stage, contain the full text of specific contractual clauses from the 6(b) orders, which remain partially non-public; the FTC's published interim report is the primary documentary anchor for this finding.
Trade Association Funding and the Advocacy Coordination Record
PCMA membership records list CVS Health, Optum Rx, and Cigna Pharmacy Management (Express Scripts) as core members providing the trade group's funding, making these same vertically integrated entities the financial base for the organization that has litigated against state-level PBM transparency requirements 3.
Public records from the Council for Affordable Health Coverage (CAHC) indicate that this coalition — led by industry consultant Joel White — promotes what it describes as "market-based" narratives that the CAHC's own public materials position in alignment with opposition to PBM fee transparency and vertical integration reform 3. The PCMA's own advocacy page, listed in the public record, frames PBM practices as cost-saving for plan sponsors and patients. The record does not currently contain financial disclosure documents quantifying the dollar flow from PCMA member companies to CAHC or other named patient advocacy groups; the connection surfaced in the record is organizational and directional, not yet quantified.
Litigation as a Structural Defense: The PCMA Docket Record
Law360 records list PCMA as a central litigant in major PBM oversight challenges, with two Supreme Court-level cases — Rutledge v. PCMA and Mulready v. PCMA — anchoring a pattern of federal litigation against state pharmacy regulation 2.
The record establishes that PCMA has pursued a recurring litigation strategy spanning thousands of dockets, though the specific law firms and economic consultancies appearing as defense counsel and expert witnesses in these proceedings have not yet been fully extracted from structured court records in the current research pass 2. Bot-protection on Law360's structured search limited direct extraction of witness lists; secondary news indices indicate that firms such as Alston & Bird and economic consultancies operate in this space, but the record at this stage does not contain a verified, case-specific list. This remains an open gap in the documentary record.
Vertical Integration: The Structural Context the Record Provides
The three entities named in PCMA's membership directory as core funders — CVS Health (CVS Caremark), Optum Rx (UnitedHealth Group), and Cigna Pharmacy Management (Express Scripts/Evernorth) — represent the same vertically integrated structures that the FTC interim report places under scrutiny for formulary design practices 1 3.
The public record, as assembled here, indicates that these entities simultaneously operate as: (1) the PBMs negotiating rebate agreements with manufacturers; (2) the insurers whose formularies those rebate agreements shape; (3) the owners of retail and specialty pharmacy chains that fill the resulting prescriptions; and (4) the primary funders of the trade association litigating against state-level disclosure requirements. The record does not yet contain audited financial data quantifying the dollar value of rebates retained versus passed through to plan sponsors or patients across these entities.
What the Record Does Not Show
Several significant gaps remain in the current documentary record:
- Rebate pass-through rates: The record does not yet contain audited figures showing what percentage of manufacturer rebates negotiated by CVS Caremark, OptumRx, or Express Scripts are retained by the PBM versus passed through to plan sponsors or patients. State Medicaid audit findings on spread pricing, referenced in the initiative charter, have not yet been surfaced in the current findings.
- Specific contractual language from 6(b) orders: The FTC's Section 6(b) special orders to Express Scripts and Zinc Health Services are referenced in the interim report, but the specific contractual conditions excluding generics have not been reproduced in the public record as extracted here. The interim report's characterization is the current evidentiary anchor.
- Quantified funding flows to advocacy coalitions: The record indicates an organizational connection between PCMA member companies and CAHC, but does not yet contain IRS Form 990 filings or other financial disclosures quantifying dollar amounts flowing to named patient advocacy groups.
- Defense counsel and expert witness rosters: The litigation record establishes PCMA's role as a central litigant, but specific law firm and economic consultancy appearances across the docket have not yet been extracted from structured court records.
- State AG actions post-July 2024: The initiative charter references subsequent state attorney general actions following the FTC interim report; these have not yet appeared in the assembled findings.
- 340B safety-net provider impact data: Federal and state agency reports on the impact of PBM formulary and reimbursement practices on 340B-covered entities have not yet been surfaced in the current research pass.